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Are They at Low or High Stroke Risk?*Menno V. Huisman, MD, PHDSEE PAGE 1385N onvalvular atrial ﬁbrillation carries a riskfor developing ischemic stroke that is low-ered by anticoagulant therapy (1). This risk
is not uniform and depends on whether a pa-
tient has either none or $1 of the following factors,
known as the CHA2DS2-VASc stroke risk score:
congestive heart failure, hypertension, age $75 years,
diabetes mellitus, stroke/transient ischemic attack,
vascular disease, age 65 to 74 years, sex category.
Both European (2) and U.S. (3) guidelines advocate
estimation of a patient’s stroke risk by use of the
CHA2DS2-VASc score for initial risk stratiﬁcation.
The European Society of Cardiology (ESC) guideline
recommends oral anticoagulant therapy (OAC) for
male patients with a CHA2DS2-VASc score $1 and for
female patients with a score $2 (the latter because
this guideline does not classify female sex as a
stand-alone risk factor). The U.S. guideline recom-
mends use of OAC at a CHA2DS2-VASc stroke risk
score $2 for patients of both sexes.
Decision making for thromboprophylaxis by
antithrombotic therapy must balance the risk of
stroke against the risk of major bleeding, especially
intracranial hemorrhage, which is the most feared
complication because it confers a high risk of death
and disability. For optimal balancing of stroke and
bleeding risk, net clinical beneﬁt has been deﬁned as*Editorials published in the Journal of the American College of Cardiology
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emboli prevented by OAC minus the rate of intra-
cranial hemorrhages attributable to OAC, multiplied
by an impact weight (4,5). A recent Markov decision
analysis model suggested that vitamin K antagonists
are preferable in patients with a stroke risk $1.7%
per year, whereas treatment with the safer non–
vitamin K oral anticoagulants should be considered
in patients with a stroke risk $0.9% per year (6).
Where do we stand in applying the CHA2DS2-VASc
score in clinical practice and how robust are the data
on which the application of CHA2DS2-VASc score in
the guidelines is currently based? There is little or no
doubt of the need for OAC in patients with CHA2DS2-
VASc scores of $2 and of the very low-risk status in
those with a CHA2DS2-VASc score of 0. However,
because there are large differences in estimates of
stroke risk without antithrombotic treatment, the real
focus of debate is in patients with a CHA2DS2-VASc
score of 1. Thus, studies have shown a 3-fold differ-
ence in the annual stroke risk in AF patients with a
CHA2DS2-VASc score of 1 and no OAC treatment,
varying from 0.6% to >2.0% (7).In this issue of the Journal, Lip et al. (8) assessed
the stroke event rate in patients with a CHA2DS2-VASc
score of 0 to 1 in a Danish hospital cohort. They
observed a 1-year rate of stroke of 0.49% (intention-
to-treat) in patients with a CHA2DS2-VASc score of
0 and a score of 1.55% (intention-to-treat) in patients
with a CHA2DS2-VASc score of 1. These rates are com-
parable to an earlier analysis from Denmark, in which
a rate of 2.01% was seen (9), but much higher than in
the original publication validating the CHA2DS2-VASc
score (10). In that publication, in the 103 patients
who participated in the Euro Heart Survey 2006
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1396registry with a CHA2DS2-VASc score of 0 and not
treated with either OAC or aspirin, the annual throm-
boembolic rate (deﬁned by ischemic stroke and other
thromboembolic events) was 0%. For the 162 patients
with a CHA2DS2-VASc score of 1, this annual risk was
0.6%. Of note, in the 2010 version of the ESC atrial
ﬁbrillation guidelines, a patient with a CHA2DS2-VASc
score of 1 has amuch higher stroke risk of 1.3% (11). This
is not a rate derived from an untreated population
but a post-hoc calculated stroke risk from analysis of
warfarin-treated patients from the 2 SPORTIF (Stroke
Prevention Using an Oral Thrombin Inhibitor in Atrial
Fibrillation) ximelagatran studies adapted for a pre-
sumed lack of effect of warfarin treatment (12). One
wonders why the 2010 ESC guidelines incorporated
this risk and not the original untreated annual stroke
risk of 0.6% from the validation study.
The rate observed in the current study by Lip et al.
(8) is also much higher than in a large Swedish cohort
recently published in the Journal (7). In that study,
the annual stroke rate was 0.1% to 0.2% for women
with a CHA2DS2-VASc score of 1; for men, the ischemic
stroke rate was 0.5% according to the Swedish Riks-
Stroke and 0.7% according to the Swedish National
Patient Register. A closer look at the study of Friberg
et al. teaches us important lessons. First, if a wide
deﬁnition of stroke was used (i.e., if it included hos-
pital discharge diagnoses of stroke, transient ischemic
attack, pulmonary embolism, arterial embolism, and
stroke not speciﬁed as ischemic or hemorrhagic), the
annual event rate for men increased by 44% to 1.3%.
Second, Friberg et al. investigated the inﬂuence of
the so-called quarantine period, used to avoid count-
ing strokes that are concomitant with the ﬁrst index
diagnosis of AF, which can lead to spuriously elevated
stroke rates. After 4 weeks, event rates stabilized at
a level almost one-half as high, as if no quarantine
period had been used. How did Lip et al. account for
these variations? According to their Online Table w3,
the 1-year stroke rates were reduced from 1.46% (con-
tinuous treatment) to 1.18% when using only primary
discharge diagnoses of ischemic stroke, and it was
lowered further to0.96%with full follow-up.This latter
ﬁgure is very near the cutoff for starting non–vitamin
K oral anticoagulants (6). Because the quarantine
period was only 14 days, it is unknown whether the
rates would have been even lower, had a longer, more
reasonable quarantine period of 4 weeks been used.The most important drawback of the current
studies is that all CHA2DS2-VASc validation exercises
have been performed by retrospective collection of
data in so-called “real-world” registries. It is there-
fore uncertain on what grounds physicians have
selected their patients for treatment with OAC,
aspirin, or no treatment. All calculations of CHA2DS2-
VASc scores in these studies have clearly been per-
formed post-hoc. Ideally, randomized trials should
clarify this issue. Importantly, ongoing, large inter-
national prospective registries, including GARFIELD
(Global Anticoagulant Registry in the FIELD) (13) and
GLORIA-AF (Global Registry on Long-Term Oral Anti-
thrombotic Treatment in Patients With Atrial Fibril-
lation) (14), which are studying the consequences of
CHA2DS2-VASc risk score estimation with respect to
starting “yes or no” with antithrombotic treatment,
may yield a more accurate estimate of the stroke risk
compared with the retrospective, single-country
(e.g., Swedish and Danish) databases that seem to
point in opposite directions (7,8).
Thus, although the CHA2DS2-VASc score has rightly
been introduced into the clinical arena as a useful
adjunct to the CHADS2 score (i.e., congestive heart
failure, hypertension [i.e., blood pressure consis-
tently above 140/90 mm Hg, or treated hypertension
on medication], age $75 years, diabetes mellitus
[1 point for presence of each], and stroke/transient
ischemic attack [2 points]), the current literature
demonstrates that the CHA2DS2-VASc score has obvi-
ously been retrospectively validated in different
patient populations, leading to markedly different
estimated stroke risks. We are therefore left with
uncertainty as to the true stroke rate in untreated
patients with a CHA2DS2-VASc score of 1. This uncer-
tainty should be incorporated into guidelines, thus
enabling clinicians to build it into the decision process
when confronted with their next patient presenting
with nonvalvular atrial ﬁbrillation. On the basis of
current evidence, there is still equipoise as to whether
a patient with a CHA2DS2-VASc score of 1 carries a
low or a high stroke risk.
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